Data as of:
LIVE
NVST
Envista Holdings Corporation · Healthcare - Dental Products
$23.69
-14.85% this month
VERSUS
COMPARE
DHR
Danaher Corporation · Healthcare - Life Science Tools & Diagnostics
$212.50
+6.47% this month
Comparison scoreboard
NVST LEADS 3/5AI Scorei
NVST 24.8
DHR ✓51.1
1Y Returni
NVST ✓+12.27%
DHR +11.57%
Fwd P/Ei
NVST ✓16.27
DHR 23.24
Target Up.i
NVST ✓+12.68%
DHR +5.50%
Op. Margini
NVST 10.39%
DHR ✓19.78%
Metrics last refreshed: 9/18/2026
Quick take
NVST vs DHR Stock Comparison: AI Score, Valuation, Performance and Upside
NVST (Envista Holdings) was spun off from DHR (Danaher) in 2019 with the dental products portfolio, while Danaher retained life science tools, diagnostics, and environmental — both companies use continuous improvement methodologies but at very different scales and in different healthcare subsectors. Danaher is a larger, more diversified platform; Envista is a focused dental products pure-play.
NVST vs DHR is focused dental products spinoff (Envista's implants and orthodontics) versus diversified healthcare and life science tools compounder (Danaher's bioprocessing, diagnostics, and DBS-powered acquisition platform) — parent versus child in life science tools and healthcare.
Live analysis · updated 9/18/2026
NVST holds the edge across 3 of 5 key metrics in this comparison. NVST leads on both 1-year return (+12.27%) and forward P/E quality (16.27x vs 23.24x for DHR), a relatively favorable combination of momentum and valuation. On fundamentals, NVST is growing revenue faster (7.10%), while DHR maintains the higher operating margin (19.78%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for NVST (+12.68%) than for DHR (+5.50%).
Normalized 1Y performance
NVST
DHR
Recent returns
NVST
DHR
Analyst price targets & sentiment
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
NVST · 12 analysts
STRONG BUYHOLDSTRONG SELL
Hold (2.6/5.0)
8 Buy / 8 Hold / 0 Sell
Price target range
analyst low$15.00
analyst mean$30.57
current price$23.69
+12.7% upside to analyst mean
DHR · 23 analysts
STRONG BUYHOLDSTRONG SELL
Strong Buy (1.4/5.0)
22 Buy / 4 Hold / 0 Sell
Price target range
analyst low$210.00
analyst high$310.00
analyst mean$227.96
current price$212.50
+5.5% upside to analyst mean
Who should consider this stock?
NVST may suit investors who:
- Want focused dental products exposure through Nobel Biocare implants, Ormco orthodontics, and iTero intraoral scanners in the growing global dental market
- Value Envista's path to independent profitability improvement as the company scales and optimizes operations following the Danaher spin-off
- See dental implant and clear aligner market growth as structural tailwinds as aging populations and increasing dental aesthetics consciousness drive treatment volumes
DHR may suit investors who:
- Want the Danaher Business System compounder with bioprocessing, diagnostics, and life science tools as the core platform — one of the most respected capital allocation track records in healthcare
- Value Cytiva's bioprocessing recovery as a catalyst for Danaher's growth re-acceleration following the 2022-2024 biopharma inventory destocking cycle
- Prefer diversified healthcare and life science exposure versus focused dental-only or pure diagnostic pure-plays
Performance & AI score
| Metric | NVST | DHR |
|---|---|---|
| AI scorei | 24.8 | 51.1 |
| AI ranki | #3082 | #483 |
| Latest closei | $23.69 | $212.50 |
| 1M returni | -14.85% | +6.47% |
| 6M returni | -6.22% | +11.78% |
| 1Y returni | +12.27% | +11.57% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | NVST | DHR |
|---|---|---|
| 1Y ago | $11.29K (+12.9%) started 2025-09-17 | $11.01K (+10.1%) started 2025-09-17 |
| 5Y ago | $5.57K (-44.3%) started 2021-09-17 | $7.63K (-23.7%) started 2021-09-20 |
| 10Y ago | $8.48K (-15.2%) started 2019-09-18 | $33.97K (+239.7%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | NVST | DHR |
|---|---|---|
| Market capi | $4.36B | $151.89B |
| Trailing P/Ei | 45.98 | 38.45 |
| Forward P/Ei | 16.27 | 23.24 |
| Price/Salesi | 1.27 | 5.89 |
| EV/Revenuei | 1.69 | 6.99 |
| Analyst targeti | $30.57 | $227.96 |
| Target upsidei | +12.68% | +5.50% |
Growth, profitability & risk
| Metric | NVST | DHR |
|---|---|---|
| Revenue growthi | 7.10% | 5.50% |
| Earnings growthi | 111.30% | 59.70% |
| EPS growthi | +111.30% | +59.70% |
| FCF margini | +9.38% | +17.23% |
| Operating margini | 10.39% | 19.78% |
| Profit margini | 3.33% | 15.95% |
| ROIC proxyi | 3.06% | 7.61% |
| Return on equityi | 3.06% | 7.61% |
| Dividend yieldi | N/A | 0.74% |
| Payout ratioi | 0.00% | 25.67% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 0.86 | 0.80 |
| Debt/equityi | 51.62 | 52.97 |
| Current ratioi | 2.42 | 1.65 |
| Quick ratioi | 1.94 | 1.15 |
Correlation
Over the past year, NVST and DHR have moved weakly in the same direction (correlation of 0.28), based on daily returns.
1Y
0.28
-1.0+1.0
5Y
0.39
-1.0+1.0
10Y
0.40
-1.0+1.0
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
NVST max drawdowni25.97%
DHR max drawdowni33.11%
NVST max wkly dropi11.64%
DHR max wkly dropi10.78%
5Y risk snapshot
NVST max drawdowni71.00%
DHR max drawdowni43.70%
NVST max wkly dropi15.22%
DHR max wkly dropi14.50%
10Y risk snapshot
NVST max drawdowni71.00%
DHR max drawdowni44.20%
NVST max wkly dropi39.19%
DHR max wkly dropi14.50%
Performance metrics by period
| Period | Metric | NVST | DHR |
|---|---|---|---|
| 1Y | Growthi | +12.92% | +10.14% |
| CAGRi | +12.94% | +10.15% | |
| Volatilityi | 37.77% | 31.46% | |
| Sharpe ratioi | 0.39 | 0.32 | |
| Sortino ratioi | 0.61 | 0.48 | |
| Max drawdowni | 25.97% | 33.11% | |
| Current drawdowni | 21.71% | 12.21% | |
| Avg drawdowni | 9.18% | 13.20% | |
| Ulcer Indexi | 11.33% | 16.40% | |
| Max daily dropi | 10.27% | 10.99% | |
| Max wkly dropi | 11.64% | 10.78% | |
| 5Y | Growthi | -44.30% | -24.89% |
| CAGRi | -11.05% | -5.57% | |
| Volatilityi | 36.39% | 29.03% | |
| Sharpe ratioi | -0.27 | -0.21 | |
| Sortino ratioi | -0.39 | -0.29 | |
| Max drawdowni | 71.00% | 43.70% | |
| Current drawdowni | 53.46% | 26.11% | |
| Avg drawdowni | 43.19% | 21.21% | |
| Ulcer Indexi | 47.56% | 23.07% | |
| Max daily dropi | 10.27% | 10.99% | |
| Max wkly dropi | 15.22% | 14.50% | |
| 10Y | Growthi | -15.24% | +225.50% |
| CAGRi | -2.34% | +12.53% | |
| Volatilityi | 39.65% | 26.17% | |
| Sharpe ratioi | 0.03 | 0.41 | |
| Sortino ratioi | 0.04 | 0.60 | |
| Max drawdowni | 71.00% | 44.20% | |
| Current drawdowni | 53.46% | 26.77% | |
| Avg drawdowni | 35.50% | 12.65% | |
| Ulcer Indexi | 42.02% | 17.13% | |
| Max daily dropi | 23.19% | 10.99% | |
| Max wkly dropi | 39.19% | 14.50% |
Business comparison
| Category | NVST | DHR |
|---|---|---|
| Company | Envista Holdings Corporation | Danaher Corporation |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Diagnostics & Research |
| Core business | Envista Holdings is a dental products company spun off from Danaher in 2019, offering dental implants, orthodontics (Ormco, iTero), and dental consumables through its Specialty Products & Technologies and Equipment & Consumables segments — serving dental practitioners globally. | Danaher is a global science and technology company providing instruments, reagents, and software for life science research (Cytiva for bioprocessing, Leica for microscopy), diagnostics (Radiometer, HemoCue), and environmental and applied solutions — operating through an acquisition and continuous improvement methodology known as the Danaher Business System (DBS). |
| Investor focus | Investors track Envista's implant market share, iTero intraoral scanner adoption, clear aligner treatment attachment rate, organic revenue growth, and the company's ability to improve operating margins as an independent company after the Danaher spin-off. | Investors track Danaher's bioprocessing revenue (Cytiva — a key biotech/biopharma tool supplier), core revenue growth, operating margin expansion through DBS, and capital allocation between organic investment and M&A. |
NVST strengths
- Strong dental implant brands (Nobel Biocare, Implant Direct) and orthodontic technology (Ormco, iTero intraoral scanner) give Envista positions in premium segments of the dental market
- Clear aligner market integration — iTero scanners are used in Invisalign workflows, creating a relationship with Align Technology and a foothold in the growing clear aligner orthodontic market
- Dental procedures are generally non-discretionary maintenance expenditures rather than purely elective, providing demand resilience through economic cycles
DHR strengths
- Danaher Business System (DBS) — the proprietary continuous improvement methodology based on Toyota Production System principles — consistently improves acquired company operating performance, creating compounding value from acquisitions
- Bioprocessing franchise (Cytiva) provides mission-critical equipment and consumables for biopharmaceutical drug manufacturing — an essential position in the biopharma supply chain
- Diversified platform across life sciences, diagnostics, and water quality provides multiple exposure to large and growing markets with different cyclical characteristics
Risks to watch — NVST
- Envista operates independently after the Danaher spin-off and must demonstrate it can grow and improve margins without Danaher's operational system (DBS) and balance sheet support
- Dental implant market competition from Straumann, Envista's Nobel Biocare, and others intensifies as market leaders compete on pricing, technology, and distribution
- Consumer spending on elective dental procedures (cosmetic work, implants) can be deferred during economic downturns, making revenue timing sensitive to consumer confidence
Risks to watch — DHR
- Bioprocessing inventory destocking cycle (2022-2024) significantly reduced Cytiva revenue as biopharma companies drew down COVID-era inventory excesses — recovery timing is critical for Danaher's growth re-acceleration
- Large acquisitions require successful DBS integration to achieve value — poor acquisition choices or integration execution can be value-destructive despite the strong DBS system
- Life science research spending is tied to NIH and private biopharma R&D budgets, which can fluctuate with government budget changes and biopharma industry spending cycles
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons